Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

NCT02033902 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT02033902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02033902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
Lead sponsor
Eisai Inc.
Phase
Observational
Overall status
Completed
Start date
June 6, 2014
Completion date
January 31, 2018
Enrollment
500 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy